Guidance

9 Sources of evidence considered by the Committee

9 Sources of evidence considered by the Committee

The diagnostics assessment report for this assessment was prepared by the Aberdeen HTA group:

Sharma P, Scotland G, Cruickshank M et al. Clinical and cost‑effectiveness of point‑of‑care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self‑monitoring of the coagulation status of people receiving long‑term vitamin K antagonist therapy compared with standard UK practice: systematic review and economic evaluation. November 2013.

Registered stakeholders

The following organisations accepted the invitation to participate in this assessment as registered stakeholders. They were invited to attend the scoping workshop and to comment on the diagnostics assessment report and the diagnostics consultation document.

Manufacturers/sponsors:

  • Roche Diagnostics

  • Alere Ltd.

Professional/specialist and patient/carer groups:

  • Atrial Fibrillation Association

  • Airedale, Wharfedale and Craven Clinical Commissioning Group

  • AntiCoagulation Europe (ACE)

  • Arrhythmia Alliance

  • British Cardiac Patients

  • British Society for Haemostasis and Thrombosis

  • Children's Heart Federation

  • Department of Health

  • Healthcare Improvement Scotland

  • HeartLine

  • Lifeblood: The Thrombosis Charity

  • Medicines and Healthcare products Regulatory Agency

  • National Clinical Guidelines Centre

  • NHS England

  • NHS Improving Quality

  • Pfizer

  • Royal College of Nursing

  • Royal College of Pathologists

  • Visea Consultancy Ltd

  • Welsh Government